Mitometh
- Generic Name
- Mitometh
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12Cl4
- CAS Number
- 107465-03-2
- Unique Ingredient Identifier
- H8MTN7XVC2
- Background
Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others. Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neu...
- Associated Conditions
- -
- Associated Therapies
- -
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 150
- Registration Number
- NCT04138992
- Locations
- 🇨🇳
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT03797625
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Yong Zhang,MD
- Target Recruit Count
- 120
- Registration Number
- NCT03086681
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Shi Yanxia
- Target Recruit Count
- 320
- Registration Number
- NCT03006614
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2016-09-20
- Target Recruit Count
- 300
- Registration Number
- NCT02907710
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT02665702
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 84
- Registration Number
- NCT02607215
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 42
- Registration Number
- NCT02606916
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2022-02-14
- Target Recruit Count
- 120
- Registration Number
- NCT02237924
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.